Reshape Lifesciences Inc (RSLS)

$3.92 +0.72 (22.50%)
Market Cap 9.35M
Revenue (ttm) 8.01M
Net Income (ttm) -7.13M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -89.01%
Debt to Equity Ratio 0.00
Volume 13,741,301
Avg Vol 3,223,008
Day's Range N/A - N/A
Shares Out 2.39M
Stochastic %K 74%
Beta 1.16
Analysts Hold
Price Target $1.00

Company Profile

ReShape Lifesciences Inc. provides products and services that manage and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company's product portfolio includes Lap-Band System to treat obesity and invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; Lap-Band 2.0 System, an adjustable postoperatively to increase or decrease the pressure to the band to optimize an individual's comfort and therapy effectiveness...

Industry: Medical Devices
Sector: Healthcare
Phone: 949 429 6680
Address:
18 Technology Drive, Suite 110, Irvine, United States
Latest News on RSLS
Vyome closes Merger Transaction, Will Trade on Nasdaq as HIND Tomorrow

Aug 14, 2025, 7:18 PM EDT - 21 days ago

Vyome closes Merger Transaction, Will Trade on Nasdaq as HIND Tomorrow

Vyome Announces Nasdaq Approval of Merger with ReShape Lifesciences, Set to Begin Trading as HIND

Aug 13, 2025, 11:50 AM EDT - 22 days ago

Vyome Announces Nasdaq Approval of Merger with ReShape Lifesciences, Set to Begin Trading as HIND

Vyome Announces New Board of Directors with Deep MIT and AI Ties

Aug 12, 2025, 9:48 AM EDT - 23 days ago

Vyome Announces New Board of Directors with Deep MIT and AI Ties

ReShape Lifesciences Announces Shareholder Approval of Merger with Vyome Therapeutics

Aug 7, 2025, 5:01 PM EDT - 4 weeks ago

ReShape Lifesciences Announces Shareholder Approval of Merger with Vyome Therapeutics

ReShape Lifesciences® Announces Partial Adjournment of Special Meeting of Stockholders

Jul 24, 2025, 4:39 PM EDT - 6 weeks ago

ReShape Lifesciences® Announces Partial Adjournment of Special Meeting of Stockholders

ReShape Lifesciences® to Host Inaugural Lap-Band® Surgeon Summit

Jul 22, 2025, 8:31 AM EDT - 6 weeks ago

ReShape Lifesciences® to Host Inaugural Lap-Band® Surgeon Summit

ReShape Lifesciences® to Host Special Meeting of Stockholders on July 24, 2025

Jul 21, 2025, 2:10 PM EDT - 6 weeks ago

ReShape Lifesciences® to Host Special Meeting of Stockholders on July 24, 2025

ReShape Lifesciences® Granted U.S. Patent Related to an Intragastric Balloon System

Jul 1, 2025, 8:31 AM EDT - 2 months ago

ReShape Lifesciences® Granted U.S. Patent Related to an Intragastric Balloon System

ReShape Lifesciences® Regains Compliance with Nasdaq Minimum Stockholders Equity Requirement

Jun 27, 2025, 9:01 AM EDT - 2 months ago

ReShape Lifesciences® Regains Compliance with Nasdaq Minimum Stockholders Equity Requirement

ReShape Lifesciences® Announces Strategic Cost Reductions and Provides Update on the Merger Agreement with Vyome Therapeutics and Asset Purchase Agreement with Biorad Medisys

Jun 26, 2025, 8:31 AM EDT - 2 months ago

ReShape Lifesciences® Announces Strategic Cost Reductions and Provides Update on the Merger Agreement with Vyome Therapeutics and Asset Purchase Agreement with Biorad Medisys

ReShape Lifesciences® Granted Key International Patent in Australia for Its Proprietary Diabetes Neuromodulation Technology

Jun 25, 2025, 8:31 AM EDT - 2 months ago

ReShape Lifesciences® Granted Key International Patent in Australia for Its Proprietary Diabetes Neuromodulation Technology

ReShape Lifesciences® Signs Exclusive Distribution Agreement with Recon Supply to Access the VA and DoD Markets

Jun 12, 2025, 8:25 AM EDT - 3 months ago

ReShape Lifesciences® Signs Exclusive Distribution Agreement with Recon Supply to Access the VA and DoD Markets

ReShape Lifesciences® Announces Pricing of $2.6 Million Public Offering

Jun 9, 2025, 9:00 AM EDT - 3 months ago

ReShape Lifesciences® Announces Pricing of $2.6 Million Public Offering

ReShape Lifesciences® Announces EU MDR Certification for Entire European and United Kingdom Product Portfolio

Jun 3, 2025, 8:31 AM EDT - 3 months ago

ReShape Lifesciences® Announces EU MDR Certification for Entire European and United Kingdom Product Portfolio

ReShape Lifesciences® Reports First Quarter Ended March 31, 2025 Financial Results and Provides Corporate Update

May 21, 2025, 8:31 AM EDT - 3 months ago

ReShape Lifesciences® Reports First Quarter Ended March 31, 2025 Financial Results and Provides Corporate Update

Orla Mining, ReShape Lifesciences And Other Big Stocks Moving Lower In Monday's Pre-Market Session

May 12, 2025, 8:32 AM EDT - 4 months ago

Orla Mining, ReShape Lifesciences And Other Big Stocks Moving Lower In Monday's Pre-Market Session

ORLA

ReShape Lifesciences Announces 1-for-25 Reverse Stock Split

May 7, 2025, 8:31 AM EDT - 4 months ago

ReShape Lifesciences Announces 1-for-25 Reverse Stock Split

ReShape Lifesciences® Presents Pre-clinical Data on Its Proprietary Diabetes Neuromodulation Device at the 12th Annual Minnesota Neuromodulation Symposium

May 2, 2025, 8:31 AM EDT - 4 months ago

ReShape Lifesciences® Presents Pre-clinical Data on Its Proprietary Diabetes Neuromodulation Device at the 12th Annual Minnesota Neuromodulation Symposium

ReShape Lifesciences® Receives Notice of Allowance for Key U.S. Patent Related to an Intragastric Balloon System

Apr 28, 2025, 8:31 AM EDT - 4 months ago

ReShape Lifesciences® Receives Notice of Allowance for Key U.S. Patent Related to an Intragastric Balloon System

ReShape Lifesciences® Receives Notice of Allowance for Additional U.S. Patent Related to Its Proprietary Diabetes Neuromodulation Technology

Apr 21, 2025, 8:31 AM EDT - 4 months ago

ReShape Lifesciences® Receives Notice of Allowance for Additional U.S. Patent Related to Its Proprietary Diabetes Neuromodulation Technology

ReShape Lifesciences Inc. (RSLS) Earnings Highlights and Strategic Business Update Conference (Transcript)

Apr 10, 2025, 5:54 PM EDT - 5 months ago

ReShape Lifesciences Inc. (RSLS) Earnings Highlights and Strategic Business Update Conference (Transcript)

ReShape Lifesciences® Partners with Motion Informatics to Bring AI-Driven Neurorehabilitation Technology to the U.S. Market

Apr 9, 2025, 4:05 PM EDT - 5 months ago

ReShape Lifesciences® Partners with Motion Informatics to Bring AI-Driven Neurorehabilitation Technology to the U.S. Market

ReShape Lifesciences® Reports Year Ended December 31, 2024 Financial Results and Provides Corporate Update

Apr 7, 2025, 4:05 PM EDT - 5 months ago

ReShape Lifesciences® Reports Year Ended December 31, 2024 Financial Results and Provides Corporate Update

RESHAPE LIFESCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of ReShape Lifesciences Inc. - RSLS

Mar 21, 2025, 11:35 AM EDT - 5 months ago

RESHAPE LIFESCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of ReShape Lifesciences Inc. - RSLS

ReShape Lifesciences® Receives Notice of Allowance for U.S. Patent Related to Its Proprietary Diabetes Neuromodulation Technology

Mar 10, 2025, 8:31 AM EDT - 6 months ago

ReShape Lifesciences® Receives Notice of Allowance for U.S. Patent Related to Its Proprietary Diabetes Neuromodulation Technology

ReShape Lifesciences® Signs Distribution Agreement in Canada With Liaison Medical for its Next-Generation Lap-Band® 2.0 FLEX

Feb 25, 2025, 8:31 AM EST - 6 months ago

ReShape Lifesciences® Signs Distribution Agreement in Canada With Liaison Medical for its Next-Generation Lap-Band® 2.0 FLEX

ReShape Lifesciences® Announces Pricing of Upsized $6.0 Million Public Offering

Feb 15, 2025, 11:17 PM EST - 7 months ago

ReShape Lifesciences® Announces Pricing of Upsized $6.0 Million Public Offering

ReShape Lifesciences® Granted Key International Patent in Israel for Its Proprietary Diabetes Neuromodulation Technology

Feb 3, 2025, 8:31 AM EST - 7 months ago

ReShape Lifesciences® Granted Key International Patent in Israel for Its Proprietary Diabetes Neuromodulation Technology

ReShape Lifesciences® Provides Update on Merger Agreement With Vyome Therapeutics and Asset Purchase Agreement With Biorad Medisys

Jan 13, 2025, 8:31 AM EST - 8 months ago

ReShape Lifesciences® Provides Update on Merger Agreement With Vyome Therapeutics and Asset Purchase Agreement With Biorad Medisys

ReShape Lifesciences Inc. (RSLS) Q3 2024 Earnings Call Transcript

Nov 14, 2024, 7:43 PM EST - 10 months ago

ReShape Lifesciences Inc. (RSLS) Q3 2024 Earnings Call Transcript

ReShape Lifesciences® to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Update

Nov 12, 2024, 4:05 PM EST - 10 months ago

ReShape Lifesciences® to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Update

ReShape Lifesciences® Receives Health Canada Approval for its Next-Generation Lap-Band® 2.0 FLEX

Nov 12, 2024, 8:31 AM EST - 10 months ago

ReShape Lifesciences® Receives Health Canada Approval for its Next-Generation Lap-Band® 2.0 FLEX

ReShape Lifesciences® Receives NIH Supplementary Grant with the University of Southern California's Center for Autonomic Nerve Recording and Stimulation Systems (CARSS) to Further Develop Next-Generation Electrodes for ReShape's Proprietary Diabetes Bloc-Stim Neuromodulation™ Technology

Nov 11, 2024, 8:31 AM EST - 10 months ago

ReShape Lifesciences® Receives NIH Supplementary Grant with the University of Southern California's Center for Autonomic Nerve Recording and Stimulation Systems (CARSS) to Further Develop Next-Generation Electrodes for ReShape's Proprietary Diabetes Bloc-Stim Neuromodulation™ Technology

ReShape Lifesciences Announces 1-for-58 Reverse Stock Split

Sep 19, 2024, 8:31 AM EDT - 1 year ago

ReShape Lifesciences Announces 1-for-58 Reverse Stock Split

ReShape Lifesciences Inc. (RSLS) Q2 2024 Earnings Call Transcript

Aug 15, 2024, 8:42 PM EDT - 1 year ago

ReShape Lifesciences Inc. (RSLS) Q2 2024 Earnings Call Transcript

ReShape Lifesciences® to Announce Financial Results for the Second Quarter Ended June 30, 2024, and Provide Corporate Update

Aug 13, 2024, 8:31 AM EDT - 1 year ago

ReShape Lifesciences® to Announce Financial Results for the Second Quarter Ended June 30, 2024, and Provide Corporate Update

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CHUY, RSLS on Behalf of Shareholders

Jul 19, 2024, 8:05 AM EDT - 1 year ago

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CHUY, RSLS on Behalf of Shareholders

CHUY

Vyome to go public and trade on the Nasdaq Capital Market under the ticker symbol “HIND”

Jul 9, 2024, 12:13 PM EDT - 1 year ago

Vyome to go public and trade on the Nasdaq Capital Market under the ticker symbol “HIND”

ReShape Lifesciences® Enters Into Merger Agreement With Vyome Therapeutics and Asset Purchase Agreement With Biorad Medisys

Jul 9, 2024, 8:31 AM EDT - 1 year ago

ReShape Lifesciences® Enters Into Merger Agreement With Vyome Therapeutics and Asset Purchase Agreement With Biorad Medisys

ReShape Lifesciences, Inc. (RSLS) Q1 2024 Earnings Call Transcript

May 17, 2024, 8:57 PM EDT - 1 year ago

ReShape Lifesciences, Inc. (RSLS) Q1 2024 Earnings Call Transcript

ReShape Lifesciences® Reports First Quarter Ended March 31, 2024 Financial Results and Provides Corporate Update

May 15, 2024, 4:05 PM EDT - 1 year ago

ReShape Lifesciences® Reports First Quarter Ended March 31, 2024 Financial Results and Provides Corporate Update

ReShape Lifesciences® to Announce Financial Results for the First Quarter Ended March 31, 2024, and Provide Corporate Update

May 14, 2024, 8:31 AM EDT - 1 year ago

ReShape Lifesciences® to Announce Financial Results for the First Quarter Ended March 31, 2024, and Provide Corporate Update

ReShape Lifesciences® Reports Year Ended December 31, 2023 Financial Results and Provides Corporate Update

Apr 1, 2024, 4:05 PM EDT - 1 year ago

ReShape Lifesciences® Reports Year Ended December 31, 2023 Financial Results and Provides Corporate Update

ReShape Lifesciences® Receives Notice of Allowance for Additional U.S. Patent Related to an Intragastric Balloon System

Mar 28, 2024, 8:31 AM EDT - 1 year ago

ReShape Lifesciences® Receives Notice of Allowance for Additional U.S. Patent Related to an Intragastric Balloon System

ReShape Lifesciences® Provides Update on 2024 Cost Reduction Plan and Reorganization to Prioritize Commercialization of Lap-Band® 2.0 FLEX

Mar 4, 2024, 8:31 AM EST - 1 year ago

ReShape Lifesciences® Provides Update on 2024 Cost Reduction Plan and Reorganization to Prioritize Commercialization of Lap-Band® 2.0 FLEX

ReShape Lifesciences® Announces First Surgeries Utilizing Next-Generation Lap-Band® 2.0 FLEX

Feb 22, 2024, 8:31 AM EST - 1 year ago

ReShape Lifesciences® Announces First Surgeries Utilizing Next-Generation Lap-Band® 2.0 FLEX

ReShape Lifesciences® Conducts Bariatric Fellows Training for its Lap-Band® System, Highlighting the Next-Generation Lap-Band® 2.0 FLEX

Jan 24, 2024, 8:31 AM EST - 1 year ago

ReShape Lifesciences® Conducts Bariatric Fellows Training for its Lap-Band® System, Highlighting the Next-Generation Lap-Band® 2.0 FLEX

ReShape Lifesciences® Engages Maxim Group LLC To Identify Strategic M&A Partnership Alternatives

Dec 20, 2023, 8:31 AM EST - 1 year ago

ReShape Lifesciences® Engages Maxim Group LLC To Identify Strategic M&A Partnership Alternatives

ReShape Lifesciences® Receives FDA PMA Supplement Approval for its Next-Generation Lap-Band® 2.0 FLEX

Dec 12, 2023, 4:05 PM EST - 1 year ago

ReShape Lifesciences® Receives FDA PMA Supplement Approval for its Next-Generation Lap-Band® 2.0 FLEX